


**Product Name** : MYCi975  
**Cat. No.** : PC-73127  
**CAS No.** : 2289691-01-4  
**Molecular Formula** : C<sub>25</sub>H<sub>16</sub>Cl<sub>2</sub>F<sub>6</sub>N<sub>2</sub>O<sub>2</sub>  
**Molecular Weight** : 561.31  
**Target** : c-Myc  
**Solubility** : 10 mM in DMSO



## Biological Activity

MYCi975 (NUCC-0200975) is a close analog of MYCi361 with improved therapeutic index, binds to **MYC** protein with KD of 2.5 uM, disrupts MYC/MAX complex formation.

MYCi975 (8 uM) enhances MYC degradation and phosphorylation on T58 in treated cells, also directly increases GSK3β-mediated MYC pT58 in the in vitro kinase assay at 6 uM.

MYCi975 inhibits MYC-dependent cancer cell viability and suppresses MYC transcriptional activity.

MYCi975 increases tolerability at significantly higher doses.

MYCi975 exhibits excellent pharmacokinetic profiles following p.o., i.p. or i.v. administration.

MYCi975 (100 mg/kg/day) inhibits tumor growth in MycCaP allografts with no changes in body weight.

MYCi975 synergized with Ara-C with no obvious impact in NSG mice bearing MV-411 AML xenografts.

## References

Han H, et al. *Cancer Cell*. 2019 Nov 11;36(5):483-497.e15.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com